Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly

Detalhes bibliográficos
Autor(a) principal: Crisostomo, Luciola M L
Data de Publicação: 2008
Outros Autores: Souza, Carlos A M, Mendes, Carlos M C, Coimbra, Silmara R, Favarato, Desiderio, Luz, Protasio L da
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/17746
Resumo: INTRODUCTION: Much evidence indicates the importance of the endothelium and hypercholesterolemia in atherosclerosis, as well as the decline in endothelial function with aging. However, it is unclear if treating dyslipidemia in elderly patients improves endothelial function and reduces C-reactive protein levels. OBJECTIVES: To evaluate vasomotor function, lipids and C-reactive protein in mildly hypertensive and hypercholesterolemic elderly patients treated with atorvastatin. METHODS: Forty-seven elderly Brazilian subjects (>; 65 years old) with LDL cholesterol (LDL-c) >; 130 mg/dL were randomly assigned, in a double-blinded manner, to receive either placebo (n = 23) or 20 mg/day of atorvastatin (n = 24) for 4 weeks. Exclusion criteria included diabetes, serious hypertension, obesity, steroid use, hormone replacement, and statin use within the previous six months. All patients underwent clinical examinations, laboratory tests (glucose, lipids, liver enzymes, creatine phosphokinase and high sensitivity C-reactive protein) and assessment of vasomotor function by high-resolution ultrasound examination of the brachial artery (flow-mediated dilation and sublingual nitrate), both before and after treatment. RESULTS: The patients were 65 to 91 years old; there was no significant difference between basal flow-mediated dilation of placebo (7.3 ± 6.1%) and atorvastatin (4.5 ± 5.1%; p = 0.20). The same was observed after treatment (6.6 ± 6.2 vs. 5.0 ± 5.6; p = 0.55). The initial nitrate dilatation (8.1 ± 5.4% vs. 10.8 ± 7.5%; p = 0.24) and that after 4 week treatment (7.1 ± 4.7% vs. 8.6 ± 5.0%; p = 0.37) were similar. Atorvastatin produced a reduction of 20% of the C-reactive protein and 42% in the LDL-c; however, there were no changes in the flow-mediated dilation. CONCLUSIONS: Atorvastatin produced a significant change of lipids and C-reactive protein; however, there were no changes in vasomotor function, suggesting the existence of intrinsic age-related vessel alterations.
id USP-19_b533f0828a50411aeccc7388ff2f3d64
oai_identifier_str oai:revistas.usp.br:article/17746
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly Endothelium^i1^sultrasonograAgedHydroximetilglutaril-CoA reductase inhibitorsC-reactive proteinLipid INTRODUCTION: Much evidence indicates the importance of the endothelium and hypercholesterolemia in atherosclerosis, as well as the decline in endothelial function with aging. However, it is unclear if treating dyslipidemia in elderly patients improves endothelial function and reduces C-reactive protein levels. OBJECTIVES: To evaluate vasomotor function, lipids and C-reactive protein in mildly hypertensive and hypercholesterolemic elderly patients treated with atorvastatin. METHODS: Forty-seven elderly Brazilian subjects (>; 65 years old) with LDL cholesterol (LDL-c) >; 130 mg/dL were randomly assigned, in a double-blinded manner, to receive either placebo (n = 23) or 20 mg/day of atorvastatin (n = 24) for 4 weeks. Exclusion criteria included diabetes, serious hypertension, obesity, steroid use, hormone replacement, and statin use within the previous six months. All patients underwent clinical examinations, laboratory tests (glucose, lipids, liver enzymes, creatine phosphokinase and high sensitivity C-reactive protein) and assessment of vasomotor function by high-resolution ultrasound examination of the brachial artery (flow-mediated dilation and sublingual nitrate), both before and after treatment. RESULTS: The patients were 65 to 91 years old; there was no significant difference between basal flow-mediated dilation of placebo (7.3 ± 6.1%) and atorvastatin (4.5 ± 5.1%; p = 0.20). The same was observed after treatment (6.6 ± 6.2 vs. 5.0 ± 5.6; p = 0.55). The initial nitrate dilatation (8.1 ± 5.4% vs. 10.8 ± 7.5%; p = 0.24) and that after 4 week treatment (7.1 ± 4.7% vs. 8.6 ± 5.0%; p = 0.37) were similar. Atorvastatin produced a reduction of 20% of the C-reactive protein and 42% in the LDL-c; however, there were no changes in the flow-mediated dilation. CONCLUSIONS: Atorvastatin produced a significant change of lipids and C-reactive protein; however, there were no changes in vasomotor function, suggesting the existence of intrinsic age-related vessel alterations. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2008-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1774610.1590/S1807-59322008000500004Clinics; Vol. 63 No. 5 (2008); 589-594 Clinics; v. 63 n. 5 (2008); 589-594 Clinics; Vol. 63 Núm. 5 (2008); 589-594 1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/17746/19811Crisostomo, Luciola M LSouza, Carlos A MMendes, Carlos M CCoimbra, Silmara RFavarato, DesiderioLuz, Protasio L dainfo:eu-repo/semantics/openAccess2012-05-22T18:30:17Zoai:revistas.usp.br:article/17746Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-22T18:30:17Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly
title Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly
spellingShingle Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly
Crisostomo, Luciola M L
Endothelium^i1^sultrasonogra
Aged
Hydroximetilglutaril-CoA reductase inhibitors
C-reactive protein
Lipid
title_short Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly
title_full Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly
title_fullStr Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly
title_full_unstemmed Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly
title_sort Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly
author Crisostomo, Luciola M L
author_facet Crisostomo, Luciola M L
Souza, Carlos A M
Mendes, Carlos M C
Coimbra, Silmara R
Favarato, Desiderio
Luz, Protasio L da
author_role author
author2 Souza, Carlos A M
Mendes, Carlos M C
Coimbra, Silmara R
Favarato, Desiderio
Luz, Protasio L da
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Crisostomo, Luciola M L
Souza, Carlos A M
Mendes, Carlos M C
Coimbra, Silmara R
Favarato, Desiderio
Luz, Protasio L da
dc.subject.por.fl_str_mv Endothelium^i1^sultrasonogra
Aged
Hydroximetilglutaril-CoA reductase inhibitors
C-reactive protein
Lipid
topic Endothelium^i1^sultrasonogra
Aged
Hydroximetilglutaril-CoA reductase inhibitors
C-reactive protein
Lipid
description INTRODUCTION: Much evidence indicates the importance of the endothelium and hypercholesterolemia in atherosclerosis, as well as the decline in endothelial function with aging. However, it is unclear if treating dyslipidemia in elderly patients improves endothelial function and reduces C-reactive protein levels. OBJECTIVES: To evaluate vasomotor function, lipids and C-reactive protein in mildly hypertensive and hypercholesterolemic elderly patients treated with atorvastatin. METHODS: Forty-seven elderly Brazilian subjects (>; 65 years old) with LDL cholesterol (LDL-c) >; 130 mg/dL were randomly assigned, in a double-blinded manner, to receive either placebo (n = 23) or 20 mg/day of atorvastatin (n = 24) for 4 weeks. Exclusion criteria included diabetes, serious hypertension, obesity, steroid use, hormone replacement, and statin use within the previous six months. All patients underwent clinical examinations, laboratory tests (glucose, lipids, liver enzymes, creatine phosphokinase and high sensitivity C-reactive protein) and assessment of vasomotor function by high-resolution ultrasound examination of the brachial artery (flow-mediated dilation and sublingual nitrate), both before and after treatment. RESULTS: The patients were 65 to 91 years old; there was no significant difference between basal flow-mediated dilation of placebo (7.3 ± 6.1%) and atorvastatin (4.5 ± 5.1%; p = 0.20). The same was observed after treatment (6.6 ± 6.2 vs. 5.0 ± 5.6; p = 0.55). The initial nitrate dilatation (8.1 ± 5.4% vs. 10.8 ± 7.5%; p = 0.24) and that after 4 week treatment (7.1 ± 4.7% vs. 8.6 ± 5.0%; p = 0.37) were similar. Atorvastatin produced a reduction of 20% of the C-reactive protein and 42% in the LDL-c; however, there were no changes in the flow-mediated dilation. CONCLUSIONS: Atorvastatin produced a significant change of lipids and C-reactive protein; however, there were no changes in vasomotor function, suggesting the existence of intrinsic age-related vessel alterations.
publishDate 2008
dc.date.none.fl_str_mv 2008-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/17746
10.1590/S1807-59322008000500004
url https://www.revistas.usp.br/clinics/article/view/17746
identifier_str_mv 10.1590/S1807-59322008000500004
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/17746/19811
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 63 No. 5 (2008); 589-594
Clinics; v. 63 n. 5 (2008); 589-594
Clinics; Vol. 63 Núm. 5 (2008); 589-594
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222753467400192